Press Release - September 1, 2016
Heidelberg, Germany, September 1, 2016 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at two upcoming investor conferences.
Credit Suisse Antibody Day
Date: Wednesday, September 7, 2016
Time: 10:40 a.m. ET
Location: New York, NY
2016 Wells Fargo Healthcare Conference
Date: Thursday, September 8, 2016
Time: 1:10 p.m. ET
Location: Boston, MA
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information please visit www.affimed.com.
Caroline Stewart, Head IR
Phone: +1 347 394 6793
E-Mail: email hidden; JavaScript is required or email hidden; JavaScript is required
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: email hidden; JavaScript is required